An overview of prostate diseases and their characteristics specific to Asian men

Asian Journal of Andrology

Volumn 14, Issue 3, 2012, Pages 458-464

  Xia, Shu Jie ^a   Cui, Di ^a   Jiang, Qi ^a  

^a SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

Author keywords

Asians; benign prostatic hyperplasia; chronic prostatitis; prostate cancer

Indexed keywords

ALFUZOSIN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; MUSCARINIC RECEPTOR BLOCKING AGENT; PHOSPHODIESTERASE V INHIBITOR; PROSTATE SPECIFIC ANTIGEN; TADALAFIL; TERAZOSIN;

ASIAN; BRACHYTHERAPY; CAUCASIAN; CHRONIC PROSTATITIS; EPIDEMIOLOGICAL DATA; GEOGRAPHIC DISTRIBUTION; HUMAN; INCIDENCE; LOWER URINARY TRACT SYMPTOM; ORGASM; PAIN; PELVIS PAIN SYNDROME; PRACTICE GUIDELINE; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE DISEASE; PROSTATE HYPERTROPHY; RACE DIFFERENCE; REVIEW; SURVIVAL RATE; SYMPTOMATOLOGY; TRANSURETHRAL RESECTION;

ASIAN CONTINENTAL ANCESTRY GROUP; CHRONIC DISEASE; DISEASE PROGRESSION; HUMANS; MALE; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; PROSTATITIS;

EID: 84860854487     PISSN: 1008682X     EISSN: 17457262     Source Type: Journal    
DOI: 10.1038/aja.2010.137     Document Type: Review

References (145)

1. Homma Y, Kawabe K, Tsukamoto T, Yamanaka H, Okada K et al. Epidemiologic survey of lower urinary tract symptoms in Asia and Australia using the international prostate symptom score. Int J Urol 1997; 4: 40-46. (Pubitemid 27129266)
2. Choi J, Ikeguchi EF, Lee SW, Choi HY, Te AE et al. Is the higher prevalence of benign prostatic hyperplasia related to lower urinary tract symptoms in Korean men due to a high transition zone index? Eur Urol 2002; 42: 7-11. (Pubitemid 35339639)
3. Lepor H, Shapiro E, Wang B, Liang YC. Comparison of the cellular composition of benign prostatic hyperplasia in Chinese and Caucasian-American men. Urology 1996; 47: 38-42. (Pubitemid 26038301)
4. Li MK, Garcia L, Patron N, Moh LC, Sundram M et al. An Asian multinational prospective observational registry of patients with benign prostatic hyperplasia, with a focus on comorbidities, lower urinary tract symptoms and sexual function. BJU Int 2008; 101: 197-202. (Pubitemid 350294053)
5. Bushman W. Etiology, epidemiology, and natural history of benign prostatic hyperplasia Urol Clin North Am 2009; 36: 403-415.
6. Byun SS, Jeong H, Jo MK, Lee E. Relative proportions of tissue components in the prostate: Are they related to the development of symptomatic BPH in Korean men? Urology 2005; 66: 593-596. (Pubitemid 41242330)
7. Rohrmann S, Nelson WG, Rifai N, Kanarek N, Basaria S et al. Serum sex steroid hormones and lower urinary tract symptoms in Third National Health and Nutrition Examination Survey (NHANES III). Urology 2007; 69: 708-713. (Pubitemid 46574931)
8. Trifiro MD, Parsons JK, Palazzi-Churas K, Bergstrom J, Lakin C et al. Serum sex hormones and the 20-year risk of lower urinary tract symptoms in communitydwelling older men. BJU Int 2010; 105: 1554-1559.
9. Sexton CC, Coyne KS, Kopp ZS, Irwin DE, Milsom I et al. The overlap of storage, voiding and postmicturition symptoms and implications for treatment seeking in the USA, UK and Sweden: EpiLUTS. BJU Int 2009; 103 Suppl 3: 12-23.
10. Irwin DE, Milsom I, Hunskaar S, Reilly K, Kopp Z et al. Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: Results of the EPIC study. Eur Urol 2006; 50: 1306-14; discussion 14-15.
11. Li MK, Garcia LA, Rosen R. Lower urinary tract symptoms and male sexual dysfunction in Asia: A survey of ageing men from five Asian countries. BJU Int 2005; 96: 1339-1354. (Pubitemid 41743935)
12. Wong SY, Leung JC, Woo J. A prospective study on the association between lower urinary tract symptoms (LUTS) and erectile dysfunction: Results from a large study in elderly Chinese in Southern China. J Sex Med 2009; 6: 2024-2031.
13. Terai A, Ichioka K, Matsui Y, Yoshimura K. Association of lower urinary tract symptoms with erectile dysfunction in Japanese men. Urology 2004; 64: 132-136. (Pubitemid 38887593)
14. Yang J, Liu JH. Association between lower urinary tract symptoms and erectile dysfunction. Zhonghua Nan Ke Xue 2006; 12: 1026-9, 34. Chinese.
15. Lavalle LL, Almagro AA, Bravo CB, Martinez LC. Lower urinary tract symptoms and erectile dysfunction. Arch Esp Urol 2010; 63: 655-662.
16. Xia SJ, Xu XX, Teng JB, Xu CX, Tang XD. Characteristic pattern of human prostatic growth with age. Asian J Androl 2002; 4: 269-271.
17. Fujikawa S, Matsuura H, Kanai M, Fumino M, Ishii K et al. Natural history of human prostate gland: Morphometric and histopathological analysis of Japanese men. Prostate 2005; 65: 355-364. (Pubitemid 41759968)
18. Chang HS, Park CH, Kim DK, Park JK, Hong SJ et al. Assessment of patient-reported outcome of patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia and treated with tamsulosin HCl in Korea. Urology 2010; 75: 1156-1161.
19. Lieber MM, Jacobson DJ, McGree ME, St Sauver JL, Girman CJ et al. Intravesical prostatic protrusion in men in Olmsted County, Minnesota. J Urol 2009; 182: 2819-2824.
20. Pinto F, Racioppi M, Sacco E, Totaro A, Brescia A et al. Progression, risk factors and subsequent medical management of symptomatic benign prostatic hyperplasia. Arch Ital Urol Androl 2009; 81: 1-8.
21. Lee SE, Chung JS, Han BK, Moon KH, Hwang SI et al. Relationship of prostatespecific antigen and prostate volume in Korean men with biopsy-proven benign prostatic hyperplasia. Urology 2008; 71: 395-398. (Pubitemid 351374707)
22. Mao Q, Zheng X, Jia X, Wang Y, Qin J et al. Relationships between total/free prostatespecific antigen and prostate volume in Chinese men with biopsy-proven benign prostatic hyperplasia. Int Urol Nephrol 2009; 41: 761-766.
23. Gupta A, Aragaki C, Gotoh M, Masumori N, Ohshima S et al. Relationship between prostate specific antigen and indexes of prostate volume in Japanese men. J Urol 2005; 173: 503-506.
24. Kehinde EO, Mojiminiyi OA, Sheikh M, Al-Awadi KA, Daar AS et al. Age-specific reference levels of serum prostate-specific antigen and prostate volume in healthy Arab men. BJU Int 2005; 96: 308-312. (Pubitemid 41097671)
25. Tsukamoto T, Masumori N, Nakagawa H, Arai Y, Komiya A et al. Changes in prostate volume in Japanese patients with benign prostatic hyperplasia: Association with other urological measures and risk of surgical intervention. Int J Urol 2009; 16: 622-627.
26. Khezri AA, Shirazi M, Ayatollahi SM, Lotfi M, Askarian M et al. Age specific reference levels of serum prostate-specific antigen, prostate volume and prostate specific antigen density in healthy Iranian men. Iran J Immunol 2009; 6: 40-48.
27. Howard DL, Taylor YJ, Ross LE. Differences in lower urinary tract symptoms, treatment and mortality among African-American and white elderly men. J Natl Med Assoc 2008; 100: 1146-1152.
28. Harkaway RC, Issa MM. Medical and minimally invasive therapies for the treatment of benign prostatic hyperplasia. Prostate Cancer Prostatic Dis 2006; 9: 204-214. (Pubitemid 44317252)
29. Smith RD, Patel A. Transurethral resection of the prostate revisited and updated. Curr Opin Urol 2011; 21: 36-41.
30. Cornu JN, Cussenot O, Haab F, Lukacs B. A widespread population study of actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia across Europe and beyond official clinical guidelines. Eur Urol 2010; 58: 450-456.
31. Xue Z, Zhang Y, Ding Q, He Z, Wang J et al. Doxazosin gastrointestinal therapeutic system versus tamsulosin for the treatment of benign prostatic hyperplasia: A study in Chinese patients. Int J Urol 2007; 14: 118-122. (Pubitemid 46121948)
32. Roehrborn CG, Siami P, Barkin J, Damiao R, Major-Walker K et al. The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 2010; 57: 123-131.
33. Greco KA, McVary KT. The role of combination medical therapy in benign prostatic hyperplasia. Int J Impot Res 2008; 20 Suppl 3: S33-43.
34. Roehrborn CG, Siami P, Barkin J, Damiao R, Becher E et al. The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study. Eur Urol 2009; 55: 461-471.
35. Miller J, Tarter TH. Combination therapy with dutasteride and tamsulosin for the treatment of symptomatic enlarged prostate. Clin Interv Aging 2009; 4: 251-258.
36. Barkin J. Management of benign prostatic hyperplasia by the primary care physician in the 21st century: The new paradigm. Can J Urol 2008; 15 Suppl 1: 21-30; discussion 30.
37. Xiao H, Li HZ, Yang Y, Huang ZM, Li YQ et al. Clinical effectiveness and safety study of combined therapy with an alpha-blocker and an anticholinergic for patients with LUT/BPH. Zhonghua Yi Xue Za Zhi 2007; 87: 1590-3. Chinese. (Pubitemid 47288889)
38. Senkul T, Yilmaz O, Iseri C, Adayener C, Akyol I et al. Comparing the therapeutic outcome of different alpha-blocker treatments for BPH in the same individuals. Int Urol Nephrol 2008; 40: 663-666.
39. Mulhall JP, Guhring P, Parker M, Hopps C. Assessment of the impact of sildenafil citrate on lower urinary tract symptoms in men with erectile dysfunction. J Sex Med 2006; 3: 662-667.
40. Tamimi NA, Mincik I, Haughie S, Lamb J, Crossland A et al.A placebo-controlled study investigating the efficacy and safety of the phosphodiesterase type 5 inhibitor UK-369,003 for the treatment of men with lower urinary tract symptoms associated with clinical benign prostatic hyperplasia. BJU Int 2010; 106: 674-680.
41. Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E. A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia. Eur Urol 2008; 53: 1236-1244.
42. Oger S, Behr-Roussel D, Gorny D, Lecoz O, Lebret T et al. Combination of doxazosin and sildenafil exerts an additive relaxing effect compared with each compound alone on human cavernosal and prostatic tissue. J Sex Med 2009; 6: 836-847.
43. Oger S, Behr-Roussel D, Gorny D, Lebret T, Denoux Y et al. Combination of alfuzosin and tadalafil exerts an additive relaxant effect on human detrusor and prostatic tissues in vitro. Eur Urol 2010; 57: 699-707.
44. Tuncel A, Nalcacioglu V, Ener K, Aslan Y, Aydin O et al. Sildenafil citrate and tamsulosin combination is not superior to monotherapy in treating lower urinary tract symptoms and erectile dysfunction. World J Urol 2010; 28: 17-22.
45. Kim MK, Cheon J, Lee KS, Chung MK, Lee JY et al. An open, non-comparative, multicentre study on the impact of alfuzosin on sexual function using the Male Sexual Health Questionnaire in patients with benign prostate hyperplasia. Int J Clin Pract 2010; 64: 345-350.
46. Kongkanand A, Chodchoy V, Lojanapiwat B, Pumpaisanchai S, Ratana-Olarn K et al. Safety and efficacy of a prolonged-release formulation of alfuzosin 10 mgonce daily in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia. J Med Assoc Thai 2009; 92: 969-978.
47. Leungwattanakij S, Watanachote D, Noppakulsatit P, Petchpaibuol T, Choeypunt N et al. Sexuality and management of benign prostatic hyperplasia with alfuzosin: SAMBA Thailand. J Sex Med 2010; 7: 3115-3126.
48. Zlotta AR, Teillac P, Raynaud JP, Schulman CC. Evaluation of male sexual function in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon), tamsulosin or finasteride. Eur Urol 2005; 48: 269-276. (Pubitemid 40957102)
49. Rosen RC, Wei JT, Althof SE, Seftel AD, Miner M et al. Association of sexual dysfunction with lower urinary tract symptoms of BPH and BPH medical therapies: Results from the BPH Registry. Urology 2009; 73: 562-566.
50. Paick JS, Cho MC, Song SH, Kim SW, Ku JH. Impacts of the quinazoline-based alpha1-Antagonist, terazosin, and of the sulfonamide derivative, tamsulosin, on serum prostate-specific antigen and prostate volume. J Korean Med Sci 2008; 23: 509-513.
51. Wang C. Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia. Curr Opin Urol 2010; 20: 49-54.
52. Reich O, Seitz M, Gratzke C, Schlenker B, Walther S et al. Benign prostatic hyperplasia (BPH): Surgical therapy options. Urologe A 2010; 49: 113-26. German.
53. Ahyai SA, Gilling P, Kaplan SA, Kuntz RM, Madersbacher S et al. Meta-Analysis of functional outcomes and complications following transurethral procedures for lower urinary tract symptoms resulting from benign prostatic enlargement. Eur Urol 2010; 58: 384-397.
54. Burke N, Whelan JP, Goeree L, Hopkins RB, Campbell K et al. Systematic review and meta-Analysis of transurethral resection of the prostate versus minimally invasive procedures for the treatment of benign prostatic obstruction. Urology 2010; 75: 1015-1022.
55. Frieben RW, Lin HC, Hinh PP, Berardinelli F, Canfield SE et al. The impact of minimally invasive surgeries for the treatment of symptomatic benign prostatic hyperplasia on male sexual function: A systematic review. Asian J Androl 2010; 12: 500-508.
56. Sim HG, Cheng CWS. Changing demography of prostate cancer in Asia. Eur J Cancer 2005; 41: 834-845. (Pubitemid 40467547)
57. Pu YS, Chiang HS, Lin CC, Huang CY, Huang KH et al. Changing trends of prostate cancer in Asia. Aging Male 2004; 7: 120-132.
58. Namiki M, Akaza H, Lee SE, Song JM, Umbas R et al. Prostate Cancer Working Group report. Jpn J Clin Oncol 2010; 40 Suppl 1: I70-5.
59. Park SK, Sakoda LC, Kang D, Chokkalingam AP, Lee E et al. Rising prostate cancer rates in South Korea. Prostate 2006; 66: 1285-1291. (Pubitemid 44384305)
60. Singh J, Xie C, Yao M, Hua S, Vignarajan S et al. Food extracts consumed in Mediterranean countries and East Asia reduce protein concentrations of androgen receptor, phospho-protein kinase B, and phospho-cytosolic phospholipase A2alpha in human prostate cancer cells. J Nutr 2010; 140: 786-791.
61. Mousavi SM. Toward prostate cancer early detection in Iran. Asian Pac J Cancer Prev 2009; 10: 413-418.
62. Pinsky PF, Kramer BS, Crawford ED, Grubb RL, Urban DA et al. Prostate volume and prostate-specific antigen levels in men enrolled in a large screening trial. Urology 2006; 68: 352-356. (Pubitemid 44175490)
63. Chiang IN, Chang SJ, Pu YS, Huang KH, Yu HJ et al. Comparison of 6- and 12-core prostate biopsy in Taiwanese men: Impact of total prostate-specific antigen, prostatespecific antigen density and prostate volume on prostate cancer detection. Urol Int 2009; 82: 270-275.
64. Bohnen AM, Groeneveld FP, Bosch JL. Serum prostate-specific antigen as a predictor of prostate volume in the community: The Krimpen study. Eur Urol 2007; 51: 1645-52; discussion 52-53.
65. Ahyai SA, Graefen M, Steuber T, Haese A, Schlomm T et al. Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level ,or54.0 ng per milliliter. Eur Urol 2008; 53: 750-757. (Pubitemid 351273880)
66. Yang WJ, Lee DH, Chung BH, Cho JS, Choi YD et al. Detection rate of prostate cancer on biopsy according to serum prostate-specific antigen in Korean men: A multicenter study. Urology 2006; 67: 333-336. (Pubitemid 43189851)
67. Kobayashi T, Mitsumori K, Kawahara T, Nishizawa K, Ogura K et al. Prostate cancer detection among men with prostate specific antigen levels of 2.5 to 4.0 ng/ml in a Japanese urological referral population. J Urol 2006; 175: 1281-1285.
68. Amirrasouli H, Kazerouni F, Sanadizade M, Sanadizade J, Kamalian N et al. Accurate cut-off point for free to total prostate-specific antigen ratio used to improve differentiation of prostate cancer from benign prostate hyperplasia in Iranian population. Urol J 2010; 7: 99-104.
69. Wang Y, Sun G, Pan JG, Guo ZJ, Li T. Performance of tPSA and f/tPSA for prostate cancer in Chinese. A systematic review and meta-Analysis. Prostate Cancer Prostatic Dis 2006; 9: 374-378. (Pubitemid 44843130)
70. You J, Cozzi P, Walsh B, Willcox M, Kearsley J et al. Innovative biomarkers for prostate cancer early diagnosis and progression. Crit Rev Oncol Hematol 2010; 73: 10-22.
71. Okada K, Okihara K, Kitamura K, Mikami K, Ukimura O et al. Community-based prostate cancer screening in Japan: Predicting factors for positive repeat biopsy. Int J Urol 2010; 17: 541-547.
72. Zhao Z, Zeng G, Zhong W. Serum early prostate cancer antigen (EPCA) as a significant predictor of incidental prostate cancer in patients undergoing transurethral resection of the prostate for benign prostatic hyperplasia. Prostate 2010; 70: 1788-1798.
73. Haese A, de la Taille A, van Poppel H, Marberger M, Stenzl A et al. Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy. Eur Urol 2008; 54: 1081-1088.
74. van Gils MP, Hessels D, Peelen WP, Vergunst H, Mulders PF et al. Preliminary evaluation of the effect of dutasteride on PCA3 in post-DRE urine sediments: A randomized, open-label, parallel-group pilot study. Prostate 2009; 69: 1624-1634.
75. Talesa VN, Antognelli C, del Buono C, Stracci F, ServaMRet al. Diagnostic potential in prostate cancer of a panel of urinary molecular tumor markers. Cancer Biomark 2009; 5: 241-251.
76. Chung BH, Hong SJ, Cho JS, Seong DH. Relationship between serum prostate-specific antigen and prostate volume in Korean men with benign prostatic hyperplasia: A multicentre study. BJU Int 2006; 97: 742-746. (Pubitemid 43383506)
77. Shim HB, Lee JK, Jung TY, Ku JH. Serum prostate-specific antigen as a predictor of prostate volume in Korean men with lower urinary tract symptoms. Prostate Cancer Prostatic Dis 2007; 10: 143-148. (Pubitemid 46881665)
78. Masumori N, Tsukamoto T, Kumamoto Y, Miyake H, Rhodes T et al. Japanese men have smaller prostate volumes but comparable urinary flow rates relative to American men: Results of community based studies in 2 countries. J Urol 1996; 155: 1324-1327. (Pubitemid 26081229)
79. Chang YL, Lin AT, Chen KK, Chang YH, Wu HH et al. Correlation between serum prostate specific antigen and prostate volume in Taiwanese men with biopsy proven benign prostatic hyperplasia. J Urol 2006; 176: 196-199. (Pubitemid 43833176)
80. Chia SE, Lau WK, Cheng C, Chin CM, Tan J et al. Prostate-specific antigen levels among Chinese, Malays and Indians in Singapore from a community-based study. Asian Pac J Cancer Prev 2007; 8: 375-378.
81. Abdallah M, Lazarev I, Ariad S, Mermershtain W. Is prostate cancer screening justified in the Bedouin population? Onkologie 2009; 32: 260-262.
82. Antenor JA, Han M, Roehl KA, Nadler RB, Catalona WJ. Relationship between initial prostate specific antigen level and subsequent prostate cancer detection in a longitudinal screening study. J Urol 2004; 172: 90-93. (Pubitemid 41615045)
83. Matsubara A, Mutaguchi K, Yasumoto H, Takeshima Y, Teishima J et al. Transrectal ultrasound-guided 10-core biopsy of the prostate for Japanese patients. Hiroshima J Med Sci 2006; 55: 65-70. (Pubitemid 44098111)
84. Jeong H, Jeong BC, Kwak C, Lee E, Lee SE et al. A comparison of prostate cancer detection rates by 12 or 6 core biopsy at different prostate-specific antigen densities in Korean men. World J Urol 2008; 26: 395-400.
85. Park HK, Lee KY, Kim KH, Jung H, Yoon SJ et al. Intermediate versus low or high prostate-specific antigen density level: Comparison of cancer detection rate between 12- and 18-core prostate biopsy. Scand J Urol Nephrol 2010; 44: 391-398.
86. Shigemura K, Arakawa S, Yamanaka K, Yasui N, Matsubara S et al. Potential predictive factors of positive prostate biopsy in the Japanese population. Int Urol Nephrol 2008; 40: 91-96. (Pubitemid 351459876)
87. Kawakami S, Numao N, Okubo Y, Koga F, Yamamoto S et al. Development, validation, and head-To-head comparison of logistic regression-based nomograms and artificial neural network models predicting prostate cancer on initial extended biopsy. Eur Urol 2008; 54: 601-611.
88. Roobol MJ, Steyerberg EW, Kranse R, Wolters T, van Den Bergh RC et al. A risk-based strategy improves prostate-specific antigen-driven detection of prostate cancer. Eur Urol 2010; 57: 79-85.
89. Roobol MJ, Schroder FH, Kranse R. A comparison of first and repeat (four years later) prostate cancer screening in a randomized cohort of a symptomatic men aged 55-75 years using a biopsy indication of 3.0 ng/ml (results of ERSPC, Rotterdam). Prostate 2006; 66: 604-612.
90. Rochester MA, Pashayan N, Matthews F, Doble A, McLoughlin J. Development and validation of risk score for predicting positive repeat prostate biopsy in patients with a previous negative biopsy in a UK population. BMC Urol 2009; 9: 7.
91. Kang SH, Bae JH, Park HS, Yoon DK, Moon DG et al. Prostate-specific antigen adjusted for the transition zone volume as a second screening test: A prospective study of 248 cases. Int J Urol 2006; 13: 910-914.
92. Oreste M, Giuseppe PG, Gianna P, Adriano A, Stefano N et al. Between-subject variations of transition zone epithelial volume and serum PSA levels in men with benign prostatic hyperplasia. World J Urol 2010; 28: 379-383.
93. Yadav R, Tu JJ, Jhaveri J, Leung RA, Rao S et al. Prostate volume and the incidence of extraprostatic extension: Is there a relation? J Endourol 2009; 23: 383-386.
94. Patel AR, Jones JS. Optimal biopsy strategies for the diagnosis and staging of prostate cancer. Current Opinion in Urology 2009; 19: 232-237.
95. Shim HB, Park HK, Lee SE, Ku JH. Optimal site and number of biopsy cores according to prostate volume prostate cancer detection in Korea. Urology 2007; 69: 902-906. (Pubitemid 46670227)
96. Pepe P, Dibenedetto G, Gulletta M, Pietropaolo F, Minaldi G et al. Prostate cancer detection after one or more negative extended needle biopsy: Results of a multicenter case-findings protocol. Arch Ital Urol Androl 2010; 82: 95-99.
97. Pepe P, Candiano G, Fraggetta F, Galia A, Grasso G et al. Is transition zone sampling at repeated saturation prostate biopsy still useful? Urol Int 2010; 85: 324-327.
98. Piros D, Fagerstrom T, Collins JW, Hahn RG. Glucose as a marker of fluid absorption in bipolar transurethral surgery. Anesth Analg 2009; 109: 1850-1855.
99. Leewansangtong S, Wiangsakunna W, Taweemankongsap T. Perioperative outcomes of open radical prostatectomy versus laparoscopic radical prostatectomy in Asian men: Comparison of two initial series by the same surgeon. Int Braz J Urol 2009; 35: 151-6; discussion 56-57.
100. Sundram M. Asian robotic experience. Urol Oncol 2010; 28: 677-681.
101. Yip S, Sim HG. Robotic radical prostatectomy in east Asia: Development, surgical results and challenges. Curr Opin Urol 2010; 20: 80-85.
102. Vassil AD, Murphy ES, Reddy CA, Angermeier KW, Altman A et al. Five year biochemical recurrence free survival for intermediate risk prostate cancer after radical prostatectomy, external beam radiation therapy or permanent seed implantation. Urology 2010; 76: 1251-1257.
103. Vu Le C, Dao OQ, Khac Tran LN. Mass screening of prostate cancer in Vietnam: Current status and our opinions. Urol Oncol 2010; 28: 673-676.
104. Fukagai T, Namiki T, Carlile RG, Namiki M. Racial differences in clinical outcome after prostate cancer treatment. Methods Mol Biol 2009; 472: 455-466.
105. Fukagai T, Namiki TS, Carlile RG, Yoshida H, Namiki M. Comparison of the clinical outcome after hormonal therapy for prostate cancer between Japanese and Caucasian men. BJU Int 2006; 97: 1190-1193. (Pubitemid 43907319)
106. Yoshioka Y. Current status and perspectives of brachytherapy for prostate cancer. Int J Clin Oncol 2009; 14: 31-36.
107. Yoshioka Y, Suzuki O, Kobayashi K, Teshima T, Yamada Y et al. External-beam radiotherapy for clinically localized prostate cancer in Osaka, Japan, 1995-2006: Time trends, outcome, and risk stratification. Strahlenther Onkol 2009; 185: 446-452.
108. Mizokami A, Ueno S, Fukagai T, Ito K, Ehara H et al. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: An Asian perspective. BJU Int 2007; 99 Suppl 1: 6-9; discussion 17-18.
109. Saito T, Kitamura Y, Komatsubara S, Matsumoto Y, Sugita T et al. Outcomes of locally advanced prostate cancer: A single institution study of 209 patients in Japan. Asian J Androl 2006; 8: 555-561. (Pubitemid 44263427)
110. Chen YC, Chuang CK, Hsieh ML, Chen WC, FanKHet al. High-dose-rate brachytherapy plus external beam radiotherapy for T1 to T3 prostate cancer: An experience in Taiwan. Urology 2007; 70: 101-105.
111. Bolla M, Fourneret P, Beneyton V, Tessier A, Jover F et al. Combination of external irradiation and androgen suppression for prostate cancer: Facts and questions. Cancer Radiother 2010; 14: 510-4. French.
112. Wu RY, Wang GM, Xu L, Zhang BH, Xu YQ et al. The feasibility and safety of highintensity focused ultrasound combined with low-dose external beam radiotherapy as supplemental therapy for advanced prostate cancer following hormonal therapy. Asian J Androl 2011; 13: 499-504
113. Xylinas E, Dache A, Roupret M. Is radical prostatectomy a viable therapeutic option in clinically locally advanced (cT3) prostate cancer? BJU Int 2010; 106: 1596-1600.
114. Clemens JQ, Markossian T, Calhoun EA. Comparison of economic impact of chronic prostatitis/chronic pelvic pain syndrome and interstitial cystitis/painful bladder syndrome. Urology 2009; 73: 743-746.
115. Calhoun EA, McNaughton Collins M, Pontari MA, O'Leary M, Leiby BE et al. The economic impact of chronic prostatitis. Arch Intern Med 2004; 164: 1231-1236. (Pubitemid 39030361)
116. Basiri A, Mousavi SM, Naghavi M, Araghi IA, Namini SA. Urologic diseases in the Islamic Republic of Iran: what are the public health priorities? East Mediterr Health J 2008; 14: 1338-1348.
117. Liang CZ, Li HJ, Wang ZP, Xing JP, Hu WL et al. Treatment of chronic prostatitis in Chinese men. Asian J Androl 2009; 11: 153-156.
118. Nickel JC. Recommendations for the evaluation of patients with prostatitis. World J Urol 2003; 21: 75-81. (Pubitemid 44175280)
119. Liang CZ, Li HJ, Wang ZP, Xing JP, Hu WL et al. The prevalence of prostatitis-like symptoms in China. J Urol 2009; 182: 558-563.
120. Krieger JN, Lee SW, Jeon J, Cheah PY, LiongMLet al. Epidemiology of prostatitis. Int J Antimicrob Agents 2008; 31 Suppl 1: S85-90.
121. Hu JC, Link CL, McNaughton-Collins M, Barry MJ, McKinlay JB. The association of abuse and symptoms suggestive of chronic prostatitis/chronic pelvic pain syndrome: Results from the Boston Area Community Health survey. J Gen Intern Med 2007; 22: 1532-7. (Pubitemid 47568688)
122. Tripp DA, Nickel JC, Ross S, Mullins C, Stechyson N. Prevalence, symptom impact and predictors of chronic prostatitis-like symptoms in Canadian males aged 16-19 years. BJU Int 2009; 103: 1080-1084.
123. Walz J, Perrotte P, Hutterer G, Suardi N, Jeldres C et al. Impact of chronic prostatitislike symptoms on the quality of life in a large group of men. BJU Int 2007; 100: 1307-1311. (Pubitemid 350043927)
124. Kunishima Y, Mori M, Kitamura H, Satoh H, Tsukamoto T. Prevalence of prostatitislike symptoms in Japanese men: Population-based study in a town in Hokkaido. Int J Urol 2006; 13: 1286-1289. (Pubitemid 44453694)
125. Lee SW, Cheah PY, Liong ML, Yuen KH, Schaeffer AJ et al. Demographic and clinical characteristics of chronic prostatitis: Prospective comparison of the University of Sciences Malaysia Cohort with the United States National Institutes of Health Cohort. J Urol 2007; 177: 153-7; discussion 58.
126. Zhou YH, Mei RB, Zhao ST, Zhang J. Sexual function and sexual life quality of chronic prostatitis patients: A clinical investigation. Zhonghua Nan Ke Xue 2010; 16: 336-40. Chinese.
127. Liang CZ, Hao ZY, Li HJ, Wang ZP, Xing JP et al. Prevalence of premature ejaculation and its correlation with chronic prostatitis in Chinese men. Urology 2010; 76: 962-966.
128. Magri V, Perletti G, Montanari E, Marras E, Chiaffarino F et al. Chronic prostatitis and erectile dysfunction: Results from a cross-sectional study. Arch Ital Urol Androl 2008; 80: 172-175.
129. Lee SW, Liong ML, Yuen KH, Leong WS, Cheah PY et al. Adverse impact of sexual dysfunction in chronic prostatitis/chronic pelvic pain syndrome. Urology 2008; 71: 79-84. (Pubitemid 351173265)
130. Schultheiss D. Urogenital infections and male sexuality: Effects on ejaculation and erection. Andrologia 2008; 40: 125-129. (Pubitemid 351379677)
131. Sonmez NC, Kiremit MC, Guney S, Arisan S, AkcaOet al. Sexual dysfunction in type III chronic prostatitis (CP) and chronic pelvic pain syndrome (CPPS) observed in Turkish patients. Int Urol Nephrol 2010; 43: 309-14
132. Kiyota H, Onodera S, Ohishi Y, Tsukamoto T, Matsumoto T. Questionnaire survey of Japanese urologists concerning the diagnosis and treatment of chronic prostatitis and chronic pelvic pain syndrome. Int J Urol 2003; 10: 636-642. (Pubitemid 38030612)
133. Ku JH, Paick JS, Kim SW. Factors influencing practices for chronic prostatitis: A nationwide survey of urologists in South Korea. Int J Urol 2005; 12: 976-983. (Pubitemid 43110234)
134. Murphy AB, Nadler RB. Pharmacotherapy strategies in chronic prostatitis/chronic pelvic pain syndrome management. Expert Opin Pharmacother 2010; 11: 1255-1261.
135. El-Nashaar A, Shamloul R. Antibiotic treatment can delay ejaculation in patients with premature ejaculation and chronic bacterial prostatitis. J Sex Med 2007; 4: 491-496. (Pubitemid 46394723)
136. Zohdy W. Clinical parameters that predict successful outcome in men with premature ejaculation and inflammatory prostatitis. J Sex Med 2009; 6: 3139-3146.
137. Tugcu V, Tasci AI, Fazlioglu A, Gurbuz G, Ozbek E et al. A placebo-controlled comparison of the efficiency of triple- and monotherapy in category III B chronic pelvic pain syndrome (CPPS). Eur Urol 2007; 51: 1113-7; discussion 18.
138. Wagenlehner FM, Schneider H, Ludwig M, Schnitker J, Brahler E et al. A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis-chronic pelvic pain syndrome: A multicentre, randomised, prospective, double-blind, placebocontrolled phase 3 study. Eur Urol 2009; 56: 544-551.
139. Murphy AB, Macejko A, Taylor A, Nadler RB. Chronic prostatitis: Management strategies. Drugs 2009; 69: 71-84.
140. Yan S, Li HZ, Zhang XY, Li HJ. Retrospective analysis of the combined therapy of terazosin with chlormezanone for chronic prostatitis/chronic pelvic pain syndrome. Zhonghua Nan Ke Xue 2009; 15: 717-20. Chinese.
141. Marszalek M, Wehrberger C, Temml C, Ponholzer A, Berger I et al. Chronic pelvic pain and lower urinary tract symptoms in both sexes: Analysis of 2749 participants of an urban health screening project. Eur Urol 2009; 55: 499-507.
142. Zaak D. Editorial comment on: Chronic pelvic pain and lower urinary tract symptoms in both sexes: Analysis of 2749 participants of an urban health screening project. Eur Urol 2009; 55: 507.
143. Laudico AV, Mirasol-Lumague MR, Mapua CA, Uy GB, Toral JA et al. Cancer incidence and survival in Metro Manila and Rizal province, Philippines. Jpn J Clin Oncol 2010; 40: 603-612.
144. Chia SE, Tan CS, Lim GH, Sim X, Lau W et al. Incidence, mortality and five-year relative survival ratio of prostate cancer among Chinese residents in Singapore from 1968 to 2002 by metastatic staging. Ann Acad Med Singapore 2010; 39: 466-471.
145. Bouchardy C, Fioretta G, Rapiti E, Verkooijen HM, Rapin CH et al. Recent trends in prostate cancer mortality show a continuous decrease in several countries. Int J Cancer 2008; 123: 421-9. (Pubitemid 351842029)